On June 23, 2022, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharmaceutical") and Italy NTC S.r.l. (hereinafter referred to as "NTC") entered into an exclusive License and Supply Agreement for the collaboration of three EU approved Class II medical device (hereinafter referred to as "Products") in China Mainland. Beimei acquire exclusive right to register and commercialize the Products in China Mainland. The Products are oral care products, suitable for children’s use, in two different dosage forms- spray and gel as topical treatment of the oral mucosa suffering from recurrent canker sores.

Oral mucosal recurrent canker sore, scientifically called recurrent aphthous ulcer, is a common clinical oral mucosal ulcer disease, which is also known as oral ulcers by the public. The incidence rate is high in China, during the attack, patients feel obvious pain, which to a certain extent bring troubles to daily life. The canker sores can appear at any age. Children who suffer canker sores could be troubled while speaking, chewing, swallowing, and their mood can be negatively affected.

The key ingredients of the Products are from nature extract, do not contain steroid, anesthetic and analgesic. The composition of the Products enables a reduction of local pain, relieving discomfort and promotes healing of canker sores, reducing their duration. The Products are colorless and taste fresh, which are friendly to patients. In particular, the Gel Junior version is fruit-flavored and convenient for topical administration that can be easily accepted by children.

This collaboration with NTC is the first attempt of Beimei Pharmaceutical in the field of medical devices. It is also the further expansion of Beimei Pharmaceutical's product line and lays the foundation for the children's oral health care.

About NTC：

NTC is an international R&D-driven pharmaceutical company headquartered in Milan - Italy, with distributors and partners in over 100 countries in the world, engaged in research, development, registration and commercialization of drugs, medical devices, and food supplements in ophthalmology, but also in other therapeutic areas like gastro-metabolism, gynecology, and pediatrics. NTC offers to its partners, currently nearly 250 companies, innovative pharmaceutical products with high quality standards.

About Beimei Pharmaceutical:

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen- China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields. Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated.